SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-286184
Filing Date
2020-11-05
Accepted
2020-11-05 07:00:32
Documents
14
Period of Report
2020-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d22329d8k.htm   iXBRL 8-K 24793
2 EX-99.1 d22329dex991.htm EX-99.1 95083
6 GRAPHIC g22329g1104211724470.jpg GRAPHIC 2047
  Complete submission text file 0001193125-20-286184.txt   257488

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20201105.xsd EX-101.SCH 3064
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20201105_lab.xml EX-101.LAB 17374
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20201105_pre.xml EX-101.PRE 10949
7 EXTRACTED XBRL INSTANCE DOCUMENT d22329d8k_htm.xml XML 3297
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 201288596
SIC: 2834 Pharmaceutical Preparations